Controversies in the management of adjuvant breast cancer with taxanes: Review of the current literature

被引：17

作者：

Araque Arroyo, Patricia ^{[1
]}

Ubago Perez, Ruth ^{[1
]}

Cancela Diez, Barbara ^{[1
]}

Fernandez Feijoo, Maria Amalia ^{[1
]}

Hernandez Magdalena, Jorge ^{[1
]}

Hernandez, Miguel Angel Calleja ^{[1
]}

机构：

[1] Virgen Nieves Univ Hosp, Dept Pharm, Granada 18012, Spain

来源：

CANCER TREATMENT REVIEWS | 2011年 / 37卷 / 02期

关键词：

Adjuvant breast cancer; Docetaxel; Paclitaxel; Taxanes; Therapy; DOXORUBICIN PLUS CYCLOPHOSPHAMIDE; PHASE-III; DOSE-DENSE; CHEMOTHERAPY; PACLITAXEL; DOCETAXEL; EPIRUBICIN; TRIAL; THERAPY; FLUOROURACIL;

D O I：

10.1016/j.ctrv.2010.06.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Taxanes offer clear benefits in adjuvant chemotherapy for early breast cancer. This review examines evidence to date on the clinical effectiveness and cost-effectiveness of their use in the adjuvant treatment of women with early breast cancer, based on three meta-analyses, one systematic review, five clinical practice guidelines and 16 randomized clinical trials. Against the background of a major increase in the use of docetaxel rather than paclitaxel in our setting over the past few years, implying a major increase in costs, we examined whether this higher use of docetaxel is supported by the available evidence. In this wide study, we found no evidence that regimens containing docetaxel yield greater benefits than those including paclitaxel. From an effectiveness standpoint, the change from paclitaxel to docetaxel in our setting is not justified. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：105 / 110

页数：6

共 50 条

[31] Controversies in breast cancer: adjuvant and neoadjuvant therapy
Montemurro, F
Redana, S
Valabrega, G
Aglietta, M
EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (07) : 1055 - 1072
[32] Adjuvant therapy approaches to breast cancer: Should taxanes be incorporated?
Edith A. Perez
Current Oncology Reports, 2003, 5 (1) : 66 - 71
[33] The Role of Taxanes in the Adjuvant Treatment of Early Stage Breast Cancer
Martine Piccart
Breast Cancer Research and Treatment, 2003, 79 (Suppl 1) : 25 - 34
[34] Adjuvant taxanes for early breast cancer - Clinical uncertainty exists
Barrett-Lee, P
Bliss, J
Ellis, P
Hall, E
Johnson, L
Lawrence, D
BRITISH JOURNAL OF CANCER, 2001, 85 : 20 - 20
[35] Breast cancer brain metastases: a review of the literature and a current multidisciplinary management guideline
M. J. Gil-Gil
M. Martinez-Garcia
A. Sierra
G. Conesa
S. del Barco
S. González-Jimenez
S. Villà
Clinical and Translational Oncology, 2014, 16 : 436 - 446
[36] Benefit with adjuvant taxanes and endocrine responsiveness in breast cancer (BC)
Martin, M.
BREAST, 2007, 16 : S9 - S10
[37] Breast cancer brain metastases: a review of the literature and a current multidisciplinary management guideline
Gil-Gil, M. J.
Martinez-Garcia, M.
Sierra, A.
Conesa, G.
del Barco, S.
Gonzalez-Jimenez, S.
Villa, S.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2014, 16 (05): : 436 - 446
[38] Adjuvant taxanes in the treatment of breast cancer: No longer at the tip of the iceberg
Dang, Chau
CLINICAL BREAST CANCER, 2006, 7 (01) : 51 - 58
[39] Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment
Vici, P.
Viola, G.
Rossi, S.
Botti, C.
Vitucci, C.
Sergi, D.
Ferranti, F. R.
Saracca, E.
Di Lauro, L.
Corsetti, S.
Foggi, P.
Fattoruso, S. I. S.
Lopez, M.
CLINICA TERAPEUTICA, 2008, 159 (06): : 453 - 456
[40] Introducing taxanes in the adjuvant treatment of breast cancer: expectations and reality
Colleoni, M
Orlando, L
Nole, F
Goldhirsch, A
BREAST, 2000, 9 (03): : 134 - 138

← 1 2 3 4 5 →